Treatment of Neck and Shoulder Pain with Botulinum Neurotoxins

Pain Practice

Volumn 4, Issue , 2004, Pages S27-S37

  Herskowitz, Allan ^a   Herskowitz, Brad ^a  

^a The Neurology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN F; CHOLINERGIC RECEPTOR BLOCKING AGENT; METIROSINE; PLACEBO; RESERPINE; TETRABENAZINE;

ARTICLE; BRAIN DEPTH STIMULATION; CEREBROVASCULAR ACCIDENT; CERVICAL DYSTONIA; CLINICAL FEATURE; DECOMPRESSION SURGERY; DISABILITY; DISEASE ASSOCIATION; DRUG EFFICACY; ELECTROSTIMULATION THERAPY; FOCAL DYSTONIA; HUMAN; MYOFASCIAL PAIN; MYOMECTOMY; MYOTOMY; NECK PAIN; PALLIDOTOMY; PATHOGENESIS; PHYSIOTHERAPY; PREVALENCE; RHIZOTOMY; SHOULDER PAIN; SPASTICITY; WHIPLASH ASSOCIATED DISORDER; WHIPLASH INJURY;

EID: 18844405751     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2004.04012.x     Document Type: Article

References (57)

1. Ferrari R, Russell AS. Neck pain. Best Pract Res Clin Rheumatol. 2002;17: 57-70.
2. Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991;41: 1088-1091.
3. Adler CH, Kumar R. Pharmacological and surgical options for the treatment of cervical dystonia. Neurology. 2000;55(suppl 5):S9-S14.
4. Brashear A. Botulinum toxin type B: a new injectable treatment for cervical dystonia. Expert Opin Investig Drugs. 2001;10: 2191-2199.
5. Waddy HM, Fletcher NA, Harding AE, Marsden CD. A genetic study of idiopathic focal dystonias. Ann Neurol. 1991;29: 320-324.
6. Defazio G, Livrea P, Guanti G, Lepore V, Ferrari E. Genetic contribution to idiopathic adult-onset blepharospasm and cranial-cervical dystonia. Eur Neurol. 1993;33: 345-350.
7. Stojanovic M, Cvetkovic D, Kostic VS. A genetic study of idiopathic focal dystonias. J Neurol. 1995;242: 508-511.
8. Brancati F, Valente EM, Castori M, et al. Role of the dopamine D5 receptor (DRD5) as a susceptibility gene for cervical dystonia. J Neurol Neurosurg Psychiatry. 2002;74: 665-666.
9. Leube B, Hendgen T, Kessler KR, Knapp M, Benecke R, Auburger G. Evidence for DYT7 being a common cause of cervical dystonia (torticollis) in Central Europe. Am J Med Genet. 1997;74: 529-532.
10. Stacy M. Idiopathic cervical dystonia: an overview. Neurology. 2000;55(suppl 5):S2-S8.
11. Rondot P, Marchand MP, Dellatolas G. Spasmodic torticollis-review of 220 patients. Can J Neurol Sci. 1991;18: 143-151.
12. Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord. 1991;6: 119-126.
13. Poewe W. Experience with botulinum toxin for cervical dystonia. In: Jankovic J, Hallett M, eds. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc.; 1994: 267-278.
14. Mandir A. Cervical dystonia (spasmodic torticollis) and other dystonias. In: Johnson RT, Griffin JW, McArthur JC, eds. Current Therapy in Neurologic Disease. St. Louis, MO: Mosby; 2002: 301-304.
15. Allergan, Inc. Data on file. A randomized, multicenter, double-blind, placebo-controlled study of intramuscular Botox® (botulinum toxin type A) purified neurotoxin complex for the treatment of cervical dystonia. 1998.
16. Arezzo JC. Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain. 2002;18(suppl 6):S125-S132.
17. Hagen K, Einarsen C, Zwart J-A, Svebak S, Bovim G. The co-occurrence of headache and musculoskeletal symptoms amongst 51 050 adults in Norway. Eur J Neurol. 2002;9: 527-533.
18. Krauss JK, Loher TJ, Pohle T, et al. Pallidal deep brain stimulation in patients with cervical dystonia and severe cervical dyskinesias with cervical myelopathy. J Neurol Neurosurg Psychiatry. 2002;72: 249-256.
19. Bovim G, Schrader H, Sand T. Neck pain in the general population. Spine. 1994;19: 1307-1309.
20. Cote P, Cassidy JD, Carroll L. The Saskatchewan Health and Back Pain Survey. The prevalence of neck pain and related disability in Saskatchewan adults. Spine. 1998;23: 1689-1698.
21. Makela M, Heliovaara M, Sievers K, Impivaara O, Knekt P, Aromaa A. Prevalence, determinants, and consequences of chronic neck pain in Finland. Am J Epidemiol. 1991;134: 1356-1367.
22. Brox JI. Shoulder pain. Best Pract Res Clin Rheumatol. 2002;17: 33-56.
23. Freund BJ, Schwartz M. Use of botulinum toxin in chronic whiplash-associated disorder. Clin J Pain. 2002;18(suppl 6):S163-S168.
24. Tsui JKC, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet. 1986;2: 245-247.
25. Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology. 1990;40: 1213-1218.
26. Lorentz IT, Subramaniam SS, Yiannikas C. Treatment of idiopathic spasmodic torticollis with botulinum-A toxin: a pilot study of 19 patients. Med J Aust. 1990;152: 528-530.
27. ®. J Neurol Neurosurg Psychiatry. 1998;64: 13-17.
28. Kessler KR, Skutta M, Benecke R, for the German Dystonia Study Group. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurol. 1999;246: 265-274.
29. O'Brien C, Brashear A, Cullis P, et al. Cervical Dystonia Severity Scale reliability study. Mov Disord. 2001;16: 1086-1090.
30. Brans JW, Lindeboom R, Aramideh M, Speelman JD. Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia. Neurology. 1998;50: 1461-1463.
31. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2002;60: 1186-1188.
32. ® Cervical Dystonia Prospective Study Group. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol. 2002;249: 57-63.
33. Greene PE, Fahn S. Response to botulinum toxin F in seronegative botulinum toxin A-resistant patients. Mov Disord. 1996;11: 181-184.
34. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997;49: 701-707.
35. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53: 1439-1446.
36. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53: 1431-1438.
37. Kumar R, Seeberger LC. Long-term safety, efficacy, and dosing of botulinum toxin type B (Myobloc) in cervical dystonia (CD) and other movement disorders [abstract P961]. Mov Disord. 2002;17(suppl 5):S292-S293.
38. Bakheit AM, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol. 2001;8: 559-565.
39. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain. 1994;59: 65-69.
40. Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine. 1998;23: 1662-1666.
41. Lang AM. Botulinum toxin type A therapy in chronic pain disorders. Arch Phys Med Rehabil. 2002;84(suppl 1):S69-S73.
42. Freund BJ, Schwartz M. Treatment of whiplash associated neck pain [corrected] with botulinum toxin-A: a pilot study. J Rheumatol. 2000;27: 481-484.
43. Brashear A, McAfee AL, Kuhn ER, Ambrosius WT. Treatment with botulinum toxin type B for upper-limb spasticity. Arch Phys Med Rehabil. 2002;84: 103-107.
44. Langlois M, Richer F, Chouinard S. New perspectives on dystonia. Can J Neurol Sci. 2002;30(suppl 1):S34-S44.
45. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope. 1998;108: 1435-1441.
46. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990;53: 633-639.
47. Zwirner P, Dressler D, Kruse E. Spasmodic laryngeal dyspnea: a rare manifestation of laryngeal dystonia. Eur Arch Otorhinolaryngol. 1997;254: 242-245.
48. Brin MF, Stewart C, Blitzer A, Diamond B. Laryngeal botulinum toxin injections for disabling stuttering in adults. Neurology. 1994;44: 2262-2266.
49. Sataloff RT, Heman-Ackah YD, Simpson LL, et al. Botulinum toxin type B for treatment of spasmodic dysphonia: a case report. J Voice. 2002;16: 422-424.
50. Benninger MS, Gardner G, Grywalski C. Outcomes of botulinum toxin treatment for patients with spasmodic dysphonia. Arch Otolaryngol Head Neck Surg. 2001;127: 1083-1085.
51. Courey MS, Garrett CG, Billante CR, et al. Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin. Ann Otol Rhinol Laryngol. 2000;109: 819-822.
52. Ross MH, Charness ME, Sudarsky L, Logigian EL. Treatment of occupational cramp with botulinum toxin: diffusion of toxin to adjacent noninjected muscles. Muscle Nerve. 1997;20: 593-598.
53. Wissel J, Kabus C, Wenzel R, et al. Botulinum toxin in writer's cramp: objective response evaluation in 31 patients. J Neurol Neurosurg Psychiatry. 1996;61: 172-175.
54. Tan EK, Jankovic J. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry. 2000;68: 186-190.
55. Blitzer A, Brin MF, Greene PE, Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol. 1989;98: 93-97.
56. Van den Bergh P, Francart J, Mourin S, Kollmann P, Laterre EC. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve. 1995;18: 720-729.
57. Comella CL, Shannon KM, Jaglin J. Extensor truncal dystonia: successful treatment with botulinum toxin injections. Mov Disord. 1998;13: 552-555.